222 related articles for article (PubMed ID: 16521323)
1. Closing the gap.
Nat Rev Drug Discov; 2006 Feb; 5(2):89. PubMed ID: 16521323
[No Abstract] [Full Text] [Related]
2. Success in translational research: lessons from the development of bortezomib.
Sánchez-Serrano I
Nat Rev Drug Discov; 2006 Feb; 5(2):107-14. PubMed ID: 16518378
[TBL] [Abstract][Full Text] [Related]
3. Development of effective new treatments for multiple myeloma.
Anderson KC; Pazdur R; Farrell AT
J Clin Oncol; 2005 Oct; 23(28):7207-11. PubMed ID: 16145064
[No Abstract] [Full Text] [Related]
4. Molecule of the month. Bortezomib.
Drug News Perspect; 2003 Jun; 16(5):324. PubMed ID: 12942163
[No Abstract] [Full Text] [Related]
5. MYC-induced sensitivity of human malignant melanoma to proteasome inhibitors - a KaMYCaze effect.
Fuchs SY
Pigment Cell Melanoma Res; 2008 Feb; 21(1):9-10. PubMed ID: 18353138
[No Abstract] [Full Text] [Related]
6. 20S ways to apoptosis.
McConkey DJ
Nat Chem Biol; 2008 Sep; 4(9):528-9. PubMed ID: 18711380
[No Abstract] [Full Text] [Related]
7. [Proteasome inhibitor bortezomib as an anticancer drug].
Yasui H; Hideshima T
Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
[No Abstract] [Full Text] [Related]
8. The role of bortezomib in the treatment of lymphoma.
Barr P; Fisher R; Friedberg J
Cancer Invest; 2007 Dec; 25(8):766-75. PubMed ID: 18058474
[TBL] [Abstract][Full Text] [Related]
9. Improvement of zoledronic-acid-induced jaw osteonecrosis with bortezomib.
Timurağaoğlu A; Ozkaynak C; Tuzuner S; Bostan F; Undar L
Acta Haematol; 2007; 118(4):203-4. PubMed ID: 17992010
[No Abstract] [Full Text] [Related]
10. Bortezomib in multiple myeloma.
Mateos MV; San Miguel JF
Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
[TBL] [Abstract][Full Text] [Related]
11. Current status of new drugs for the treatment of patients with multiple myeloma.
Kenealy M; Prince HM
Intern Med J; 2006 Dec; 36(12):781-9. PubMed ID: 17096741
[TBL] [Abstract][Full Text] [Related]
12. An audience with...Joseph Bolen. Interview by Bethan Hughes.
Bolen J
Nat Rev Drug Discov; 2009 Aug; 8(8):608. PubMed ID: 19644470
[TBL] [Abstract][Full Text] [Related]
13. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
Caravita T; de Fabritiis P; Palumbo A; Amadori S; Boccadoro M
Nat Clin Pract Oncol; 2006 Jul; 3(7):374-87. PubMed ID: 16826218
[TBL] [Abstract][Full Text] [Related]
15. [Anticancer chemotherapy: transfer of biological concepts to clinical research].
Belpomme D
Bull Cancer; 1991; 78(12):1097-103. PubMed ID: 1786422
[No Abstract] [Full Text] [Related]
16. Targeted therapy--possible new therapeutic option for malignant mesothelioma?
Dobra K; Hjerpe A
Connect Tissue Res; 2008; 49(3):270-2. PubMed ID: 18661358
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib in the front-line treatment of multiple myeloma.
Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
[TBL] [Abstract][Full Text] [Related]
18. Use of intrapleural bortezomib in myelomatous pleural effusion.
Iannitto E; Minardi V; Tripodo C
Br J Haematol; 2007 Nov; 139(4):621-2. PubMed ID: 17979947
[No Abstract] [Full Text] [Related]
19. Velcade and vitamin C: too much of a good thing?
Catley L; Anderson KC
Clin Cancer Res; 2006 Jan; 12(1):3-4. PubMed ID: 16397016
[No Abstract] [Full Text] [Related]
20. Newer treatment options for patients in first relapse. From the Multiple Myeloma Research Foundation.
Richardson P
Oncology (Williston Park); 2006 May; 20(6):633-8. PubMed ID: 16773847
[No Abstract] [Full Text] [Related]
[Next] [New Search]
